Lupin Pharma Canada is pleased to announce that ZAXINE® is now listed across all Canadian provinces with the recent addition of PEI coverage.
The coverage criteria for PEI (special authority criteria) as of July 23, 2018 are:
For reducing the risk of overt hepatic encephalopathy (HE) recurrence (i.e., ≥2 episodes) in patients who meet the following criteria:
Patients are unable to achieve adequate control of HE recurrence with maximal tolerated dose of lactulose alone.
Must be used in combination with maximal tolerated doses of lactulose.
For patients not maintained on lactulose, information is required regarding the nature of the patient’s intolerance to lactulose.
For more information, click here.